SI-BONE Finally Has All Three Catalysts Live — and Still Won't Guide 2027
Onyx is cleared and in alpha launch, the new Granite DRGs went live October 1, and opex guidance came down. So why is the stock 10% off its high?
SIBN · Earnings Call · 2026-11-02
Three catalysts, one quarter
For most of its public life SI-BONE has run a single, repeating story: roughly 20% revenue growth, gross margins near 80%, and an operating line that kept refusing to cross zero. This quarter did not break the mold on the top line — $55.7 million, up 14.5%, with U.S. revenue of $52.8 million riding a genuinely impressive 19.5% procedure volume growth — but it is the first quarter in which all three of the company's long-telegraphed catalysts are simultaneously live rather than anticipated. Revenue has compounded ~357% since 2018, yet the recent quarterly prints cluster in the mid-teens — which is precisely why the setup matters more than the print. One: iFuse Granite Onyx received FDA 510(k) clearance in September and entered an alpha launch in October, with full launch set for January. Laura Francis was unusually direct about the read-through from those first thirty days: “Early demand is tracking ahead of Granite over the comparable launch period.” — Laura Francis, Chief Executive Officer · 2026-11-02 Two: the new Granite DRGs took effect October 1. This is the point the market has been slow to price. The prior NTAP expired October 1, 2025 — meaning for twelve months Granite had no add-on payment at all — and the replacement is structurally better: up to $50,000 of incremental hospital payment per qualifying case, and critically, all-payer rather than Medicare-only. Three: proposed CMS changes for SI joint fusion (hospital outpatient above $20,000, ASC above $16,000, a new $20,000 office payment for CPT 27279) sit one final rule away from a January 1, 2027 start.What management quietly stopped selling
The most interesting shift this quarter is not what got added but what got demoted. For three straight quarters the Smith+Nephew trauma partnership was a headline growth pillar — in August, Francis said plainly that “the cases are underway.” — Laura Francis, Chief Executive Officer · 2026-08-03 On this call it became a courtesy paragraph: no KPIs, no penetration metrics, and when asked directly, the answer was that working with a larger partner “does tend to take a little bit more time.” — Laura Francis, Chief Executive Officer · 2026-11-02 The keyword history confirms it — pelvic trauma was one of the company's sharpest keyword decliners this quarter after ranking near the top of the trajectory in earlier periods. Similarly, INTRA Ti, the Q1 star with the strongest keyword momentum of any SI-BONE theme eighteen months ago, has been absorbed into a generic "INTRA platform" mention. That is not a negative — it is what successful products look like once they stop needing to be sold on calls — but it does mean the narrative weight has rotated decisively from trauma and interventional SI joint toward complex fusion.The ASP crack worth watching
Here is where the story has friction. U.S. procedure volume grew 19.5% while U.S. revenue grew 13.9%. That gap is procedure mix and site of care: a growing share of Granite cases used two implants rather than four, and INTRA platform adoption in ASCs and offices carries structurally lower ASP. This is a real, not cosmetic, dilution — and it sits against a global tape that is also rewarding ambulatory surgery center exposure, so the site-of-care migration is a genuine tailwind with a price tag. Anshul Maheshwari expects the direction to reverse: “you should see an improvement in ASP in the fourth quarter given the dynamics the way they're playing out.” — Anshul Maheshwari, Chief Financial Officer · 2026-11-02 The mechanism is credible — cases combining Granite and Onyx are running about six implants per procedure — but it is also the single assumption the Q4 guidance leans on hardest.The 2027 punt
The headline tension of the call was guidance philosophy. The press release claimed the strongest foundation for growth acceleration in company history; the Street is at ~15.5% for 2027, below SI-BONE's own long-run average. Asked to square that, Maheshwari listed six tailwinds and then declined entirely.That is a defensible answer in November. It is also, notably, the same answer the company gave in August, when the DRGs were merely proposed — and the same structure of answer it gave in May, when Francis called the DRG proposal “a very significant and underappreciated tailwind.” — Laura Francis, Chief Executive Officer (CEO) · 2026-05-11 The difference now is that the tailwind is banked rather than hoped for, and opex guidance was trimmed to 10.5% growth from 12%. Operating margin has improved from -32% two years ago to -8.6% last reported, with management pointing toward GAAP profitability and gross margin at 79.5% remains genuinely industry-leading. Meanwhile Price to Revenue of 3.4x is down 75% from the 2021 peak. In other words, the market has already stopped paying for growth and started paying for a P&L — which is exactly what the operating-leverage story now has to deliver.We feel good about the growth prospects into 2027, but we want to get a few more months behind us from a performance standpoint before we talk about 2027.